期刊
CELLS
卷 8, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/cells8060536
关键词
prognosis; FGF19; FGFR4; HCC; inhibitors
类别
资金
- Korea Health Industry Development Institute - Ministry of Health andWelfare [HI16C1985]
- Gachon University Gil Medical Center [FRD2016-20]
- Higher Education Commission of Pakistan through National Research Program For Universities (NRPU) [7036]
Hepatocellular carcinoma (HCC) is the sixth most common type of cancer, with an increasing mortality rate. Aberrant expression of fibroblast growth factor 19-fibroblast growth factor receptor 4 (FGF19-FGFR4) is reported to be an oncogenic-driver pathway for HCC patients. Thus, the FGF19-FGFR4 signaling pathway is a promising target for the treatment of HCC. Several pan-FGFR (1-4) and FGFR4-specific inhibitors are in different phases of clinical trials. In this review, we summarize the information, recent developments, binding modes, selectivity, and clinical trial phases of different available FGFR4/pan-FGF inhibitors. We also discuss future perspectives and highlight the points that should be addressed to improve the efficacy of these inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据